Tiline Pharma: what changed
Tiline Pharma
Largest movements
- Receivables within one year +€16,000
new in 2025: €16,000
- Cash +€852
up €852 (+1.6%), from €54,638 to €55,491
mainly Net result for the year (+€16,560) and Other debts (+€3,644)
- Reserves +€16,560
up €16,560 (+61.2%), from €27,067 to €43,627
- Other debts +€3,644
up €3,644 (+88.9%), from €4,098 to €7,742
- Tax, wage and social debts -€3,195
down €3,195 (-18.2%), from €17,558 to €14,363
- Gross operating margin -€11,149
down €11,149 (-31.5%), from €35,415 to €24,266
- Taxes -€3,232
down €3,232 (-32.9%), from €9,828 to €6,597
- Other operating charges +€404
up €404 (+222%), from €182 to €585
- Financial charges +€396
up €396 (+310%), from €128 to €524
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €54,638 | €71,491 | +€16,852 | +30.8% |
| Current assets | 29/58 | €54,638 | €71,491 | +€16,852 | +30.8% |
| Amounts receivable within one year | 40/41 | - | €16,000 | +€16,000 | |
| Other amounts receivable | 41 | - | €16,000 | +€16,000 | |
| Cash at bank and in hand | 54/58 | €54,638 | €55,491 | +€852 | +1.6% |
| Total equity and liabilities | 10/49 | €54,638 | €71,491 | +€16,852 | +30.8% |
| Equity | 10/15 | €32,067 | €48,627 | +€16,560 | +51.6% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €27,067 | €43,627 | +€16,560 | +61.2% |
| Distributable reserves | 133 | €27,067 | €43,627 | +€16,560 | +61.2% |
| Amounts payable | 17/49 | €22,571 | €22,863 | +€292 | +1.3% |
| Amounts payable within one year | 42/48 | €22,355 | €22,444 | +€89 | +0.4% |
| Trade debts | 44 | €699 | €339 | -€360 | -51.5% |
| Suppliers | 440/4 | €699 | €339 | -€360 | -51.5% |
| Taxes, remuneration and social security | 45 | €17,558 | €14,363 | -€3,195 | -18.2% |
| Taxes | 450/3 | €17,558 | €14,363 | -€3,195 | -18.2% |
| Other amounts payable | 47/48 | €4,098 | €7,742 | +€3,644 | +88.9% |
| Accrued charges and deferred income | 492/3 | €216 | €419 | +€203 | +94.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €0 | - | = | |
| Other operating charges | 640/8 | €182 | €585 | +€404 | +222% |
| Gross operating margin | 9900 | €35,415 | €24,266 | -€11,149 | -31.5% |
| Operating profit (loss) | 9901 | €35,233 | €23,680 | -€11,553 | -32.8% |
| Financial charges | 65/66B | €128 | €524 | +€396 | +310% |
| Recurring financial charges | 65 | €128 | €524 | +€396 | +310% |
| Profit (loss) for the period before taxes | 9903 | €35,105 | €23,157 | -€11,949 | -34.0% |
| Income taxes | 67/77 | €9,828 | €6,597 | -€3,232 | -32.9% |
| Profit (loss) for the period | 9904 | €25,277 | €16,560 | -€8,717 | -34.5% |
| Profit (loss) for the period to be appropriated | 9905 | €25,277 | €16,560 | -€8,717 | -34.5% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.